22 mars 2025
15 mars 2025
Results of a study on lenacapavir and two broadly neutralizing antibodies were presen…
At the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco, results were presented from a Phase II study examining the efficacy of a combination of lenacapavir (TN Sunlenca) and two broadly
11 mars 2025
Recherche Consultant.e : Co-Animation d’Atelier et Rédaction de Rapport –…
Contexte : La région du Moyen-Orient et de l’Afrique du Nord (MENA) continue de faire face à des défis majeurs en matière de santé publique liés au VIH/sida. Les populations clés, notamment les jeunes, les
11 mars 2025
Call for Talents: Transform the Fight against HIV with ADP-MENA (Activists Developmen…
Context: The Middle East and North Africa (MENA) region continues to face major public health challenges related to HIV/AIDS. Key populations, including young people, men who have sex with men, sex workers, and injecting
11 mars 2025
Appel à Talents : Transformez la Lutte contre le VIH avec ADP-MENA
***(Activists Development Program in MENA Region) Contexte : La région du Moyen-Orient et de l’Afrique du Nord (MENA) continue de faire face à des défis majeurs en matière de santé publique liés au VIH/sida. Les
7 mars 2025
In Argentina, Gilead’s patent applications for lenacapavir have been rejected
The National Institute of Industrial Property of Argentina (INPI) has rejected patent applications from Gilead for the drug lenacapavir – an innovative long-acting injectable drug that has proven effective as an option for PrEP
6 mars 2025
TERMS OF REFERENCE FOR AUDIOVISUAL AGENCY FOR GLOBAL SUMMIT 2025
ABOUT ITPC-MENA ITPC-MENA is a regional non-governmental organization operating in the MiddleEast and North Africa region bringing together a network of community activistsunited by our vision of a longer, healthier, more productive life for people
6 mars 2025